Latest News and Press Releases

LONDON, Sept. 16, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2004. Announced today * AS1404...

LONDON, Sept. 16, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2004. Announced today * AS1404...

LONDON, May 13, 2004 (PRIMEZONE) -- Antisoma plc (LSE:ASM), the biotechnology company developing novel anti-cancer drugs, today announces its results for the three months ended 31 March 2004. ...

LONDON, UK, March 29, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, announces the presentation of promising new data from...

LONDON, March 22, 2004 (PRIMEZONE) -- Antisoma plc (LSE:ASM), the biopharmaceutical company specialising in the development of novel anti-cancer drugs, will today hold an R&D update for analysts...

LONDON, Feb. 24, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the appointment of Dr Ursula Ney as Chief...

LONDON, Sept. 10, 2003 (PRIMEZONE) -- Antisoma plc, (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) the biopharmaceutical company specialising in novel anti-cancer drugs, today announces that it has...

LONDON, and PRINCETON, N.J., Sept. 9, 2003 (PRIMEZONE) -- Antisoma plc (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation...

London, UK, August 26, 2003 (PRIMEZONE) -- Antisoma (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF), the UK-based biopharmaceutical company, today announces that it has received approval for a...

LONDON, Aug. 22, 2003 (PRIMEZONE) -- Antisoma (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be...